OS Therapies (OSTX) Stock Price, News & Analysis

Company Overview

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Key Stats

• Today's Range: $2.21 to $2.32
• 50-Day Range: $1.56 to $2.50
• 52-Week Range: $1.12 to $7.00
• Volume: 234,344 shs
• Average Volume: 722,358 shs
• Market Capitalization: $70.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Buy

OS Therapies Stock Analysis - MarketRank™

OS Therapies scored higher than 35% of companies evaluated by MarketBeat, and ranked 799th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

OS Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

OS Therapies has a consensus price target of $18.00, representing about 707.2% upside from its current price of $2.23.

Amount of Analyst Coverage

OS Therapies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OS Therapies are expected to grow in the coming year, from ($0.64) to ($0.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OS Therapies is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OS Therapies is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.18% of the float of OS Therapies has been sold short.

Short Interest Ratio / Days to Cover

OS Therapies has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OS Therapies does not currently pay a dividend.

Dividend Growth

OS Therapies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.18% of the float of OS Therapies has been sold short.

Short Interest Ratio / Days to Cover

OS Therapies has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for OS Therapies this week, compared to 2 articles on an average week.

Search Interest

Only 16 people have searched for OSTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added OS Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OS Therapies insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.30% of the stock of OS Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.

OSTX Stock Analysis - Frequently Asked Questions

How have OSTX shares performed this year?

OS Therapies' stock was trading at $4.28 at the start of the year. Since then, OSTX stock has decreased by 47.9% and is now trading at $2.23.

When did OS Therapies IPO?

OS Therapies (OSTX) raised $8 million in an IPO on Thursday, August 1st 2024. The company issued 2,000,000 shares at $4.00 per share. Brookline Capital Markets (Division of Arcadia Securities LLC) acted as the underwriter for the IPO.

Who are OS Therapies' major shareholders?

Top institutional investors of OS Therapies include XTX Topco Ltd (0.12%) and Bridgeway Capital Management LLC (0.09%).
View institutional ownership trends.

How do I buy shares of OS Therapies?

Shares of OSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OS Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OS Therapies investors own include AST SpaceMobile (ASTS), Energy Transfer (ET), Black Stone Minerals (BSM), Kinder Morgan (KMI), Main Street Capital (MAIN), Atlas Energy Solutions (AESI) and Chevron (CVX).

Company Calendar

• Today: 9/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:OSTX
• Previous Symbol: NYSE:OSTX
• CIK: 1795091
• Web: N/A
• Phone: (410) 297-7793
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OS Therapies: $18.00
• High Price Target: $20.00
• Low Price Target: $15.00
• Potential Upside/Downside: +700.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -569.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.76
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 31,645,000
• Free Float: N/A
• Market Cap: $71.20 million
• Optionable: N/A
• Beta: N/A